- Open Access
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
© Flatmark et al; licensee BioMed Central Ltd. 2006
Received: 20 June 2006
Accepted: 03 August 2006
Published: 03 August 2006
The tumor response to preoperative radiotherapy of locally advanced rectal cancer varies greatly, warranting the use of experimental models to assay the efficacy of molecular targeting agents in rectal cancer radiosensitization. Histone deacetylase (HDAC) inhibitors, agents that cause hyperacetylation of histone proteins and thereby remodeling of chromatin structure, may override cell cycle checkpoint responses to DNA damage and amplify radiation-induced tumor cell death.
Human colorectal carcinoma cell lines were exposed to ionizing radiation and HDAC inhibitors, and cell cycle profiles and regulatory factors, as well as clonogenicity, were analyzed.
In addition to G2/M phase arrest following irradiation, the cell lines displayed cell cycle responses typical for either intact or defective p53 function (the presence or absence, respectively, of radiation-induced expression of the cell cycle inhibitor p21 and subsequent accumulation of G1 phase cells). In contrast, histone acetylation was associated with complete depletion of the G1 population of cells with functional p53 but accumulation of both G1 and G2/M populations of cells with defective p53. The cellular phenotypes upon HDAC inhibition were consistent with the observed repression of Polo-like kinase-1, a regulatory G2/M phase kinase. Following pre-treatment with HDAC inhibitors currently undergoing clinical investigation, the inhibitory effect of ionizing radiation on clonogenicity was significantly amplified.
In these experimental models, HDAC inhibition sensitized the tumor cells to ionizing radiation, which is in accordance with the concept of increased probability of tumor cell death when chromatin structure is modified.
Standard treatment of rectal cancer that by clinical or radiological assessment reveals locally advanced growth within the pelvis involves preoperative radiotherapy aimed at down-staging the tumor, to facilitate subsequent surgical excision [1, 2]. However, tumor response to preoperative therapy varies greatly from pathological complete response to lack of objective response, warranting the use of experimental models to assay the efficacy of molecular targeting agents in rectal cancer radiosensitization.
The combination of radiotherapy and chemotherapy is advocated primarily because of the independent effect of each modality. Chemotherapeutics enhance radiocytotoxicity by means of increasing the initial DNA damage, inhibiting DNA repair, or slowing down cellular repopulation during fractionated radiotherapy, which are mechanisms that essentially depend on cell cycle synchronization of the tumor cell population . Theoretically, such synchronization is achieved when sub-lethal DNA damage is applied to the tumor cells, by means of activation of signaling pathways that are rapidly manifested as arrests at cell cycle checkpoints .
Massive insult on DNA, such as double-strand DNA breaks following cellular exposure to ionizing radiation, may induce checkpoint responses in essentially any phase of the cell cycle , ultimately leading to the outcome of cell survival if DNA is properly repaired or, if not, cell death . The signaling pathway via the tumor-suppressor protein p53, the primary regulator of the G1 checkpoint, is often defective in human solid tumors. In tumor cells with intact p53 function, however, DNA damage leads to rapid p53 stabilization and subsequent induction of the G1 phase inhibitor p21 . The mechanism of DNA damage-activated G2 checkpoint signaling, initiated by ATM, involves inhibition of the enzymatic activity of Polo-like kinase-1 (Plk1) and subsequent delay in activation of the G2/M transition kinase . We have previously found that cell cycle arrest of breast carcinoma cell lines at the G2/M boundary comprises repression of the gene for Plk1, PLK [7–9].
A variety of pharmacological compounds, designed to target cell cycle regulatory mechanisms, have been shown to override the DNA damage defense response that prevents mitotic entry . Such agents may have therapeutic potential as radiosensitizers by facilitating cell death by mitotic catastrophe, and a wide array of compounds are undergoing clinical development .
Drugs that modify the cellular chromatin structure may also radiosensitize tumor cells. Taxanes, which disrupt chromatin structure and chromosome segregation in mitotis, are currently utilized clinically as radiosensitizers in treatment of non-small cell lung cancer and head-and-neck cancer . Cellular treatment with HDAC inhibitors causes hyperacetylation of histone proteins, which leads to remodeling of chromatin structure . In addition to this, the pertubation by HDAC inhibitors of cell cycle checkpoint signaling  might constitute the cellular mechanism by which these compounds enhance tumor cell sensitivity to radiation treatment. Currently, seven HDAC inhibitors are under investigation in clinical trials .
In a previous report we compared cell cycle responses of a human breast carcinoma cell line to ionizing radiation and HDAC inhibition . The cell line we used required rather high concentrations of the HDAC inhibitor, trichostatin A (TSA), to reveal histone acetylation. Moreover, we chose to treat the cell line with a high radiation dose (8 Gy) to possibly achieve clearly defined effects on the cell cycle phenotype. In these breast carcinoma cells, the G2 phase responses to ionizing radiation were closely similar to those observed upon TSA treatment .
The frequency of TP53 mutations in colorectal cancer is 40–50% . Hence, in the present study we have compared colorectal carcinoma cell lines with wild-type or mutated TP53, to evaluate the use of HDAC inhibitors in combination with ionizing radiation in rectal cancer. As valid experimental conditions for rectal cancer therapy, we measured inhibitory effects of ionizing radiation on clonogenicity after exposure to radiation doses of 2 or 5 Gy, which are fractionation doses used in preoperative treatment of locally advanced disease [1, 17], and the possible radiosensitization by suberoylanilide hydroxamic acid (SAHA; currently licensed as vorinostat) or the benzamide MS-275, which are HDAC inhibitors in clinical development .
Cell lines and experimental treatments
The origin of the human colorectal carcinoma cell lines is delineated previously . The HCT116 and SW620 cell lines were purchased from ATCC (Manassas, VA, USA). The Co115 cell line was obtained from Dr. B. Sordat (Swiss Institute of Experimental Cancer Research, Epalinges, Switzerland), whereas the KM20L2 cell line was provided by Dr. M. R. Boyd (National Cancer Institute, Frederick, MD, USA). All cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum and 2.0 mM glutamine. High-energy radiation from a 60Co source was delivered at a rate of approximately 0.6 Gy/minute. The unirradiated control cells were simultaneously placed in room temperature to obtain comparable conditions. The commercially available HDAC inhibitors TSA and SAHA were obtained from Sigma-Aldrich Norway (Oslo, Norway), whereas the HDAC inhibitor MS-275 was a generous gift from Schering AG (Berlin, Germany).
Flow cytometry analysis
Cells were harvested in ice-cold phosphate-buffered saline, centrifuged, and fixed in 100% methanol. To determine the fractions of cells in G1, S, and G2/M phases from the cell cycle distribution, the cells were stained with 1.5 μg/ml Hoechst 33258 in phosphate-buffered saline and analyzed in a FACStar+ flow cytometer (Becton Dickinson, San Jose, CA, USA), as described previously .
Western blot analysis
Protein expression was measured by means of standard Western blot technique, as described previously , and all experiments were performed two or three independent times. The membranes were immunostained with designated primary antibodies obtained from Zymed Laboratories Inc. (San Francisco, CA, USA), Santa Cruz Biotechnology (Santa Cruz, CA, USA), Calbiochem/Merck Biosciences Ltd. (Nottingham, UK), or Upstate (Lake Placid, NY, USA). These were anti-Plk1 (Zymed; 33–1700), anti-p53 (SC-6243), anti-Cyclin D1 (SC-20044), anti-p21 (SC-6246), anti-α-tubulin (Calbiochem; CP06), anti-acetyl-histone H3 (Upstate; 06–599), and anti-acetyl-histone H4 (Upstate; 06–866), respectively.
Northern blot analysis
Expression of RNA was measured by means of standard Northern blot technique, as described previously . The human cDNA clone for PLK was obtained from RZPD Deutsches Ressourcenzentrum für Genomforschung GmbH (Berlin, Germany). The human cDNA probe for CCND1 was a gift from Dr. D. Beach (Howard Hughes Medical Institute, Cold Spring Harbor, NY, USA), and the human cDNA probe for CDKN1A was a gift from Dr. B. Vogelstein (The John Hopkins University School of Medicine, Baltimore, MD, USA). To evaluate the amounts of RNA loaded, the filters were rehybridized to a kinase-labeled oligonucleotide probe complementary to nucleotides 287–305 of human 18S rRNA.
Assessment of clonogenicity
Clonogenic regrowth efficiency was determined by plating single cells suspended in medium. The cells were left for 6 hours to allow attachment to the plastic before the medium was replaced by media with or without HDAC inhibitors. Following 18 hours incubation, the media were changed to fresh medium (without any drug) and the cells immediately irradiated. The appropriate plating density was aimed to produce 20–40 surviving colonies in each well of six-well culture plates. After incubation for 7 days, the cell colonies were fixed and stained with 0.1% crystal violet. Colonies of ≥ 50 cells were counted for computing of surviving fraction. At least three parallel samples were scored in three to five repetitions performed for each treatment condition.
Cell cycle responses to ionizing radiation
Following radiation exposure of the wild-type TP53 Co115 cell line, the percentage of G2 phase cells was gradually increasing, while a distinct G1 population was maintained during the observation period (Figure 1, second panel from top). In these cells, p53 stabilization and resulting induction in CDKN1A mRNA and p21 protein as well as repression of PLK mRNA and Plk1 protein were seen (Figure 2). These response profiles to DNA damage were highly correlated to the observed changes in cell cycle redistribution. The KM20L2 cell line displayed lack of G1 checkpoint protein responses but increased Plk1 expression upon irradiation (Figure 2). As seen from the lower panel of Figure 1, this cell line showed distinct DNA damage-induced G2/M phase arrest but with a small G1 population present during the entire observation period.
Cell cycle responses to TSA
Ionizing radiation and HDAC inhibition by TSA – clonogenicity
Moreover, the possible radiosensitizing effect of TSA, essentially by amplifying the inhibitory effect of ionizing radiation on clonogenicity, was measured. Based on the histone acetylation data (Figure 3) and the observed redistribution of cell cycle phases (Figure 4), we chose to analyze the cell lines upon incubation with 30 and 100 nM concentrations of TSA for 18 hours before the HDAC inhibitor was removed and the cells irradiated. With these incubation conditions, unirradiated HCT116 cells showed surviving fractions of ~0.5 and ~0.35 with 30 and 100 nM TSA, respectively, whereas relative SW620 colony formation was ~0.6 with both TSA concentrations. As seen from Figure 6, the cytotoxic effect of ionizing radiation on both HCT116 and SW620 cell lines seemed to be amplified by TSA, but interestingly more pronounced with the lower concentration.
Ionizing radiation and HDAC inhibition by SAHA or MS-275 – clonogenicity
In this report we have compared cell cycle response profiles of human colorectal carcinoma cell lines to ionizing radiation and HDAC inhibition. In addition to G2/M phase arrest following radiation exposure, the cell lines displayed cell cycle responses typical for either intact or defective p53 function. In contrast to the profiles induced by irradiation, HDAC inhibition was associated with complete depletion of the G1 phase population of cells with functional p53 but accumulation of both G1 and G2/M phase populations of cells with defective p53. Moreover, histone acetylation was followed by significant reduction in clonogenic regrowth of irradiated cells, irrespective of p53 status. This observation is in accordance with the concept of increased probability of tumor cell death when the chromatin structure is modified.
Each cell line's p53 status was also confirmed by sequence analysis of the TP53 gene, by means of methodology described previously . In both cell lines with TP53 mutation (SW620 and KM20L2), a base substitution of A for a G nucleotide in codon 273, resulting in change of amino acid Arg to His, was detected (data not shown). According to the International Agency for Research on Cancer's TP53 Mutation Database , this particular base substitution represents ~5% of all TP53 mutations recorded in colorectal carcinomas. The frequency of mutations in the hotspot codon 273 in an international cohort of colorectal carcinoma patients was recently reported to be 8% , which may be regarded as a substantial fraction of patients with TP53-mutated colorectal tumors.
In a variety of tumor cell models, pharmacological inhibition of HDAC activity has been shown to cause redistribution of cell cycle profiles resembling G2 checkpoint responses to DNA damage [7, 20–23]. Although accumulation in G1 phase has been reported [22, 23, 26, 27], induction of the G1 phase inhibitor p21 and concomitant hypophosphorylation of the retinoblastoma protein upon HDAC inhibition have been shown to occur without subsequent G1 checkpoint arrest . Our findings do not clarify the issue of whether p21 may be involved. In the SW620 cells, TSA treatment was associated with maintained G1 population in the absence of any p21 expression. Furthermore, the finding that a G1 population reappeared in TSA-treated HCT116 cells is more likely due to release of cells arrested in G2/M phase than to a concurrent p21 induction.
Although p21 as well as the principal G1 phase cyclin, Cyclin D1, are considered targets for regulation by HDAC inhibition [28–30], regulatory responses of these cell cycle factors to TSA were not convincingly displayed by HCT116 or SW620 cells. In contrast, repression of the G2/M phase kinase Plk1 was clearly observed in both TSA-treated cell lines, consistent with the G2/M phase accumulation concurrently seen. The TSA-directed decline in PLK mRNA expression is in accordance with our previous finding . PLK is among several genes, encoding mitotic regulators, of which mRNA expression is down-regulated following activation of the G2 checkpoint . Apart from the Co115 cell line and contrary to our observations in various breast carcinoma cells lines [7–9, 19], however, Plk1 was found to be up-regulated rather than down-regulated upon irradiation.
In tumor cell lines, cytotoxicity of chemotherapeutics and the anti-Her2 antibody trastuzumab has been found increased by the presence of SAHA and MS-275 [21, 32, 33]. Recently, MS-275 was also shown to sensitize tumor cell lines to the growth-inhibitory effect of retinoic acid . Among HDAC inhibitors in clinical investigation, five have been reported to act as radiosensitizers in preclinical models [26, 35–40]. Interestingly, in animal models, topical skin application of HDAC inhibitors significantly suppressed cutaneous side effects of radiotherapy , suggesting that the contemporary approach of molecularly targeted therapy may be utilized to increase the therapeutic ratio between the tumor and surrounding normal tissues in radiotherapy. To our knowledge, the present report is the first to study HDAC inhibition as radiosensitizing strategy with therapeutically relevant radiation doses in colorectal cancer.
In contrast to what was observed with SAHA and MS-275, a threshold concentration of TSA (30–100 nM) seemed to be necessary to obtain cellular acetylation of core histones H4 and H3. Histone acetylation was clearly present with 30 nM TSA after 12 hours incubation but absent after 24 hours, whereas with 100 nM, hyperacetylation was maintained after 24 hours. Identical observations were done in other colorectal carcinoma cell lines (data not shown). Yet, following pre-treatment for 18 hours, the lower TSA concentration (30 nM) was found to sensitize both cell lines (HCT116 and SW620) to the inhibitory effect of ionizing radiation on clonogenicity, while the higher concentration (100 nM) seemed less efficacious. A similar phenomenon has been reported after experimental in vivo use of MS-275, as inhibition of osteolytic bone metastases seemed to be more efficient with the lower therapy dose . It has previously been shown that TSA also acts via mechanisms involving acetylation of non-histone proteins, which might be of consequence for TSA-induced cytotoxicity . Moreover, it has been suggested that different classes of HDAC inhibitors may cause differential protein acetylation and, to a certain degree, differential gene expression [43, 44]. Such differences in effector mechanisms might account for the apparent feature of TSA contra SAHA and MS-275 to whether the histone acetylation status might directly predict the compounds' efficacy of sensitizing the tumor cells to DNA-damaging therapy.
While TSA has shown excessive toxicity under in vivo conditions, both SAHA and MS-275 have reached clinical investigation [45–47]. The development and early therapeutic utilization of such compounds demand biomarker(s) that may provide direct insight into their mode of action. The complexity of effector mechanisms involved with TSA is probably a main reason why this agent is not feasible to monitor and, hence, use safely in the in vivo setting.
There is strong scientific evidence that chromatin-remodeling drugs may radiosensitize tumor cells. The present report indicates that histone acetylation is associated with enhanced radiocytotoxicity in colorectal carcinoma cell lines, irrespective of their TP53 mutation status. Whether such information might translate into strategies to improve radiotherapy outcome in rectal cancer, requires further experimental approaches but hints, if anything, at an appealing concept.
We sincerely thank Schering AG for the gift of MS-275. The research activity of K.F. is funded by The Norwegian Research Council (grant 160604/V50) and of R.V.N. and A.H.R. by The Norwegian Cancer Society (grants C-02132 and C-04083, respectively).
- Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E: A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003, 42: 476-492. 10.1080/02841860310012301View ArticlePubMedGoogle Scholar
- Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schidberger H, Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351: 1731-1740. 10.1056/NEJMoa040694View ArticlePubMedGoogle Scholar
- Milas L, Mason KA, Liao Z, Ang KK: Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003, 25: 152-167. 10.1002/hed.10232View ArticlePubMedGoogle Scholar
- Kastan MB, Bartek J: Cell-cycle checkpoints and cancer. Nature 2004, 432: 316-323. 10.1038/nature03097View ArticlePubMedGoogle Scholar
- Fei P, El-Deiry WS: P53 and radiation responses. Oncogene 2003, 22: 5774-5783. 10.1038/sj.onc.1206677View ArticlePubMedGoogle Scholar
- Barr FA, Sillje HHW, Nigg EA: Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004, 5: 429-440. 10.1038/nrm1401View ArticlePubMedGoogle Scholar
- Nome RV, Bratland Å, Harman G, Fodstad Ø, Andersson Y, Ree AH: Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol Cancer Ther 2005, 4: 1231-1238. 10.1158/1535-7163.MCT-04-0304View ArticlePubMedGoogle Scholar
- Ree AH, Bratland Å, Nome RV, Stokke T, Fodstad Ø: Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1. Oncogene 2003, 22: 8952-8955. 10.1038/sj.onc.1207000View ArticlePubMedGoogle Scholar
- Ree AH, Bratland Å, Nome RV, Stokke T, Fodstad Ø, Andersson Y: Inhibitory targeting of checkpoint kinase signaling impairs radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization? Radiother Oncol 2004, 72: 305-310. 10.1016/j.radonc.2004.07.002View ArticlePubMedGoogle Scholar
- Zhou BBS, Bartek J: Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer 2004, 4: 1-10. 10.1038/nrc1296View ArticleGoogle Scholar
- Deutsch E, Soria JC, Armand JP: New concepts for phase I trials: evaluating new drugs combined with radiation therapy. Nat Clin Pract Oncol 2005, 2: 456-465. 10.1038/ncponc0295View ArticlePubMedGoogle Scholar
- Choy H: Taxanes in combined modality therapy for solid tumors. Crit Rev Oncol Hematol 2001, 37: 237-247.View ArticlePubMedGoogle Scholar
- Johnstone RW, Licht JD: Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003, 4: 13-18. 10.1016/S1535-6108(03)00165-XView ArticlePubMedGoogle Scholar
- Beamish H, Warrener R, Gabrielli BG: Analysis of checkpoint responses to histone deacetylase inhibitors. Methods Mol Biol 2004, 281: 245-259.PubMedGoogle Scholar
- Kelly WK, Marks PA: Drug insight: histone deacetylase inhibitors – development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2: 150-157. 10.1038/ncponc0106View ArticlePubMedGoogle Scholar
- Iacopetta B: TP53 mutation in colorectal cancer. Hum Mutat 2003, 21: 271-276. 10.1002/humu.10175View ArticlePubMedGoogle Scholar
- Tankel K, Hay J, Ma R, Toy E, Larsson S, MacFarlane J: Short-course preoperative radiation therapy for operable rectal cancer. Am J Surg 2002, 183: 509-511. 10.1016/S0002-9610(02)00832-2View ArticlePubMedGoogle Scholar
- Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø: Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer 2004, 40: 1593-1598. 10.1016/j.ejca.2004.02.023View ArticlePubMedGoogle Scholar
- DeMasters GA, Gupta MS, Jones KR, Cabot M, Wang H, Gennings C, Park M, Bratland A, Ree AH, Gewirtz DA: Potentiation of cell killing by fractionated radiation and suppression of proliferative recovery in MCF-7 breast tumor cells by the vitamin D(3) analog EB 1089. J Steroid Biochem Mol Biol 2004, 92: 365-374. 10.1016/j.jsbmb.2004.07.011View ArticlePubMedGoogle Scholar
- Atadja P, Gao L, Kwon P, Trogani N, Walker H, Hsu M, Yeleswarapu L, Chandramouli N, Perez L, Versace R, Wu A, Sambucetti L, Lassota P, Cohen D, Bair K, Wood A, Remiszewski S: Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res 2004, 64: 689-695. 10.1158/0008-5472.CAN-03-2043View ArticlePubMedGoogle Scholar
- Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K: Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of Her-2. Clin Cancer Res 2005, 11: 6382-6389. 10.1158/1078-0432.CCR-05-0344View ArticlePubMedGoogle Scholar
- Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE: Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002, 1: 937-941.PubMedGoogle Scholar
- Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP: Histone deacetylase inhibitors have profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004, 10: 1141-1149. 10.1158/1078-0432.CCR-03-0100View ArticlePubMedGoogle Scholar
- The International Agency for Research on Cancer's TP53 Mutation Database[http://www-p53.iarc.fr]
- Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N: The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005, 23: 7518-7528. 10.1200/JCO.2005.00.471View ArticlePubMedGoogle Scholar
- Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP: SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006, 15: 187-191.PubMedGoogle Scholar
- Zhang Y, Jung M, Dritschilo A, Jung M: Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004, 161: 667-674. 10.1667/RR3192View ArticlePubMedGoogle Scholar
- Ju R, Muller MT: Histone deacetylase inhibitors activate p21[WAF1] expression via ATM. Cancer Res 2003, 63: 2891-2897.PubMedGoogle Scholar
- Gui CY, Ngo L, Xu WS, Richon VM, Marks PA: Histone deacetylase (HDAC) inhibitor activation of p21[WAF1] involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004, 101: 1241-1246. 10.1073/pnas.0307708100PubMed CentralView ArticlePubMedGoogle Scholar
- Alao JP, Lam EWF, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM: Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 2004, 10: 8094-8104. 10.1158/1078-0432.CCR-04-1023View ArticlePubMedGoogle Scholar
- Crawford DF, Piwnica-Worms H: The G(2) DNA damage checkpoint delays expression of genes encoding mitotic regulators. J Biol Chem 2001, 276: 37166-37177. 10.1074/jbc.M103414200View ArticlePubMedGoogle Scholar
- Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F: Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003, 63: 7291-7300.PubMedGoogle Scholar
- Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S: The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 2004, 64: 2590-2600. 10.1158/0008-5472.CAN-03-2631View ArticlePubMedGoogle Scholar
- Wang XF, Qian DZ, Ren M, Kato Y, Wei Y, Zhang L, Fansler Z, Clark D, Nakanishi O, Pili R: Epigenetic modulation of retinoic acid receptor [beta]2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005, 11: 3535-3542. 10.1158/1078-0432.CCR-04-1092View ArticlePubMedGoogle Scholar
- Camphausen K, Burgan W, Cerra M, Oswald KA, Trepel JB, Lee MJ, Tofilon PJ: Enhanced radiation-induced cell killing and prolongation of [gamma]H2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 2004, 64: 316-321. 10.1158/0008-5472.CAN-03-2630View ArticlePubMedGoogle Scholar
- Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H, Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 2005, 114: 380-386. 10.1002/ijc.20774View ArticlePubMedGoogle Scholar
- Camphausen K, Scott T, Sproull M, Tofilon PJ: Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin Cancer Res 2004, 10: 6066-6071. 10.1158/1078-0432.CCR-04-0537View ArticlePubMedGoogle Scholar
- Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM: Modulation of radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2005, 62: 223-229. 10.1016/j.ijrobp.2004.12.088View ArticlePubMedGoogle Scholar
- Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE: Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005, 11: 4912-4922. 10.1158/1078-0432.CCR-04-2088View ArticlePubMedGoogle Scholar
- Zhang Y, Adachi M, Zhao X, Kawamura R, Imai K: Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino-methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells. Int J Cancer 2004, 110: 301-308. 10.1002/ijc.20117View ArticlePubMedGoogle Scholar
- Chung YL, Wang AJ, Yao LF: Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol Cancer Ther 2004, 3: 317-325.View ArticlePubMedGoogle Scholar
- Onyia JE, Galvin RJS, Ma YL, Halladay DL, Miles RR, Yang X, Fuson T, Cain RL, Zeng QQ, Chandrasekhar S, Emkey R, Xu Y, Thirunavukkarasu K, Bryant HU, Martin TJ: Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther 2004, 309: 369-379. 10.1124/jpet.103.057893View ArticlePubMedGoogle Scholar
- Glaser KB, Li J, Pease LJ, Staver MJ, Marcotte PA, Guo J, Frey RR, Garland RB, Heyman HR, Wada CK, Vasudevan A, Michaelides MR, Davidsen SK, Curtin ML: Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem Biophys Res Commun 2004, 325: 683-690. 10.1016/j.bbrc.2004.10.082View ArticlePubMedGoogle Scholar
- Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK: Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003, 2: 151-163.PubMedGoogle Scholar
- Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005, 23: 3923-3931. 10.1200/JCO.2005.14.167PubMed CentralView ArticlePubMedGoogle Scholar
- O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK: Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006, 24: 166-173. 10.1200/JCO.2005.01.9679View ArticlePubMedGoogle Scholar
- Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 23: 3912-3922. 10.1200/JCO.2005.02.188View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.